Plasma exchange in systemic autoimmune diseases;Recambio plasmático en las enfermedades autoinmunes sistémicas

Seminarios de la Fundacion Espanola de Reumatologia

Volumn 14, Issue 2, 2013, Pages 43-50

  Pons Estel, Guillermo J ^a   Serrano, Rosa ^a   Lozano, Miguel ^a   Cid, Joan ^a   Cervera, Ricard ^a   Espinosa, Gerard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Apheresis; Plasma exchange; Systemic autoimmune diseases

Indexed keywords

ANTIBODY; COMPLEMENT; CYTOKINE;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE CLONE; PLASMAPHERESIS; SHORT SURVEY; TISSUE INJURY;

EID: 84877101273     PISSN: 15773566     EISSN: 19883099     Source Type: Journal    
DOI: 10.1016/j.semreu.2013.02.002     Document Type: Short Survey

References (82)

1. Abel J.J., Rowntree L.G., Turner B.B. Plasma removal with return of corpuscles (plasmaphaeresis). The Journal of Pharmacology and experimental therapeutics Vol. V. No. 6, July, 1914. Transfus Sci 1990, 11:166-177.
2. McCarthy L.J. The challenge of evidence-based medicine for apheresis. Ther Apher Dial 2003, 7:153-154.
3. Jaffe I.A. Comparison of the effect of plasmapheresis and penicillamine on the level of circulating rheumatoid factor. Ann Rheum Dis 1963, 22:71-76.
4. Terman D.S., Durante D., Buffaloe G., McIntosh R. Attenuation of canine nephrotoxic glomerulonephritis with an extracorporeal immunoadsorbent. Scand JImmunol 1977, 6:195-202.
5. Terman D.S., Buffaloe G., Mattioli C., Cook G., Tillquist R., Sullivan M., et al. Extracorporeal immunoadsorption: Initial experience in human systemic lupus erythematosus. Lancet 1979, 2:824-827.
6. Smith J.W., Weinstein R., Hillyer K.L. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 2003, 43:820-822.
7. Madore F., Lazarus J.M., Brady H.R. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996, 7:367-386.
8. Lozano M., Mazzara R. Importance of language. Lancet 2003, 361:1750.
9. Abel J.J. Crystalline insulin. Proc Natl Acad Sci U S A 1926, 12:132-136.
10. Okafor C., Ward D.M., Mokrzycki M.H., Weinstein R., Clark P., Balogun R.A. Introduction and overview of therapeutic apheresis. J Clin Apher 2010, 25:240-249.
11. Pons-Estel G.J., Salerni G.E., Serrano R.M., Gomez-Puerta J.A., Plasin M.A., Aldasoro E., et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev 2011, 10:679-684.
12. Szczepiorkowski Z.M., Winters J.L., Bandarenko N., Kim H.C., Linenberger M.L., Marques M.B., et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010, 25:83-177.
13. Ma T.H., Cabrera G.L., Chen R., Gill B.S., Sandhu S.S., Vandenberg A.L., et al. Tradescantia micronucleus bioassay. Mutat Res 1994, 310:221-230.
14. Ma T.H., Cabrera G.L., Cebulska-Wasilewska A., Chen R., Loarca F., Vandenberg A.L., et al. Tradescantia stamen hair mutation bioassay. Mutat Res 1994, 310:211-220.
15. Felson D.T., LaValley M.P., Baldassare A.R., Block J.A., Caldwell J.R., Cannon G.W., et al. The Prosorba column for treatment of refractory rheumatoid arthritis: A randomized, double-blind, sham-controlled trial. Arthritis Rheum 1999, 42:2153-2159.
16. Shemin D., Briggs D., Greenan M. Complications of therapeutic plasma exchange: A prospective study of 1,727 procedures. J Clin Apher 2007, 22:270-276.
17. Basic-Jukic N., Kes P., Glavas-Boras S., Brunetta B., Bubic-Filipi L., Puretic Z. Complications of therapeutic plasma exchange: Experience with 4857 treatments. Ther Apher Dial 2005, 9:391-395.
18. Bramlage C.P., Schroder K., Bramlage P., Ahrens K., Zapf A., Muller G.A., et al. Predictors of complications in therapeutic plasma exchange. J Clin Apher 2009, 24:225-231.
19. Raad I.I., Luna M., Khalil S.A., Costerton J.W., Lam C., Bodey G.P. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994, 271:1014-1016.
20. Weinstein R. Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange. J Clin Apher 2001, 16:210-211.
21. Mokrzycki M.H., Kaplan A.A. Therapeutic plasma exchange: Complications and management. Am J Kidney Dis 1994, 23:817-827.
22. Hedayati N., Schomisch S.J., Carino J.L., Timothy Sherwood J., Lesnefsky E.J., Cmolik B.L. Cardioprotection by St Thomas' solution is mediated by protein kinase C and tyrosine kinase. J Surg Res 2003, 113:121-127.
23. Balogun R.A., Kaplan A., Ward D.M., Okafor C., Burns T.M., Torloni A.S., et al. Clinical applications of therapeutic apheresis. J Clin Apher 2010, 25:250-264.
24. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926.
25. Guyatt G., Gutterman D., Baumann M.H., Addrizzo-Harris D., Hylek E.M., Phillips B., et al. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an american college of chest physicians task force. Chest [Review] 2006, 129:174-181.
26. Casian A., Jayne D. Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. Curr Opin Rheumatol 2011, 23:12-17.
27. Geltner D., Kohn R.W., Gorevic P., Franklin E.C. The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement. Arthritis Rheum 1981, 24:1121-1127.
28. Ferri C., Gremignai G., Bombardieri S., Moriconi L., Pontrandolfo A., Vitali C., et al. Plasma-exchange in mixed cryoglobulinemia. Effects on renal, liver and neurologic involvement. Ric Clin Lab 1986, 16:403-411.
29. Stefanutti C., Vivenzio A., Di Giacomo S., Labbadia G., Mazza F., D'Alessandri G., et al. Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia. J Clin Apher 2009, 24:241-246.
30. Russo G.E., Caramiello M.S., Vitaliano E., Marco C.M., Pennacchia M., Giusti S., et al. Haemorheological changes in mixed cryoglobulinaemia during apheresis treatment. Transfus Sci 1996, 17:499-503.
31. Pietrogrande M., de Vita S., Zignego A.L., Pioltelli P., Sansonno D., Sollima S., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011, 10:444-454.
32. Gomez-Puerta J.A., Hernandez-Rodriguez J., Lopez-Soto A., Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest 2009, 136:1101-1111.
33. Lee R.W., D'Cruz D.P. Pulmonary renal vasculitis syndromes. Autoimmun Rev 2010, 9:657-660.
34. Jayne D.R., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F., Guillevin L., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18:2180-2188.
35. De Lind van Wijngaarden R.A., Hauer H.A., Wolterbeek R., Jayne D.R., Gaskin G., Rasmussen N., et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol 2007, 18:2189-2197.
36. Walsh M., Catapano F., Szpirt W., Thorlund K., Bruchfeld A., Guillevin L., et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011, 57:566-574.
37. Szpirt W.M., Heaf J.G., Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial. Nephrol Dial Transplant 2011, 26:206-213.
38. Guillevin L., Pagnoux C. Indication for plasma exchange for systemic necrotizing vasculidities. Transfus Apher Sci 2007, 36:179-185.
39. Guillevin L., Lhote F., Gayraud M., Cohen P., Jarrousse B., Lortholary O., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996, 75:17-28.
40. Pagnoux C., Mahr A., Cohen P., Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: Analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 2005, 84:115-128.
41. Parry H.F., Moran C.J., Snaith M.L., Richards J.D., Goldstone A.H., Nineham L.J., et al. Plasma exchange in systemic lupus erythematosus. Ann Rheum Dis 1981, 40:224-228.
42. Wei N., Klippel J.H., Huston D.P., Hall R.P., Lawley T.J., Balow J.E., et al. Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983, 1:17-22.
43. Schroeder J.O., Euler H.H. Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Adv Exp Med Biol 1989, 260:203-213.
44. Szczepiorkowski Z.M., Bandarenko N., Kim H.C., Linenberger M.L., Marques M.B., Sarode R., et al. Guidelines on the use of therapeutic apheresis in clinical practice: Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007, 22:106-175.
45. Szczepiorkowski Z.M., Shaz B.H., Bandarenko N., Winters J.L. The new approach to assignment of ASFA categories--introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apher 2007, 22:96-105.
46. Lewis E.J., Hunsicker L.G., Lan S.P., Rohde R.D., Lachin J.M. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992, 326:1373-1379. The Lupus Nephritis Collaborative Study Group.
47. Lewis E.J. Plasmapheresis therapy is ineffective in SLE. J Clin Apher 1992, 7:153. Lupus Nephritis Collaborative Study Group.
48. Wallace D.J., Goldfinger D., Pepkowitz S.H., Fichman M., Metzger A.L., Schroeder J.O., et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher 1998, 13:163-166.
49. Euler H.H., Schroeder J.O., Harten P., Zeuner R.A., Gutschmidt H.J. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994, 37:1784-1794.
50. Danieli M.G., Palmieri C., Salvi A., Refe M.C., Strusi A.S., Danieli G. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher 2002, 17:72-77.
51. Neuwelt C.M. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 2003, 7:173-182.
52. Bartolucci P., Brechignac S., Cohen P., Le Guern V., Guillevin L. Adjunctive plasma exchanges to treat neuropsychiatric lupus: A retrospective study on 10 patients. Lupus 2007, 16:817-822.
53. Kimura K.Y., Seino Y., Hirayama Y., Aramaki T., Yamaguchi H., Amano H., et al. Systemic lupus erythematosus related transverse myelitis presenting longitudinal involvement of the spinal cord. Intern Med 2002, 41:156-160.
54. Lin C.H., Jeng J.S., Yip P.K. Plasmapheresis in acute disseminated encephalomyelitis. J Clin Apher 2004, 19:154-159.
55. Menge T., Hemmer B., Nessler S., Wiendl H., Neuhaus O., Hartung H.P., et al. Acute disseminated encephalomyelitis: An update. Arch Neurol 2005, 62:1673-1680.
56. Khurana D.S., Melvin J.J., Kothare S.V., Valencia I., Hardison H.H., Yum S., et al. Acute disseminated encephalomyelitis in children: Discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. Pediatrics 2005, 116:431-436.
57. Canas C., Tobon G.J., Granados M., Fernandez L. Diffuse alveolar hemorrhage in Colombian patients with systemic lupus erythematosus. Clin Rheumatol 2007, 26:1947-1949.
58. Starck M., Abedinpour F., Dendorfer U., Wagner-Czekalla J., Pachmann M., Mann J.F., et al. Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression--report of two cases. Eur J Haematol 2005, 75:436-440.
59. Espinosa G., Cervera R. Antiphospholipid syndrome: Frequency, main causes and risk factors of mortality. Nat Rev Rheumatol 2010, 6:296-300.
60. Uthman I., Shamseddine A., Taher A. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus Apher Sci 2005, 33:11-17.
61. Cervera R., Bucciarelli S., Plasin M.A., Gomez-Puerta J.A., Plaza J., Pons-Estel G., et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the «CAPS Registry». J Autoimmun 2009, 32:240-245.
62. Cervera R. Catastrophic antiphospholipid syndrome (CAPS): Update from the «CAPS Registry». Lupus 2010, 19:412-418.
63. Espinosa G., Bucciarelli S., Cervera R., Lozano M., Reverter J.C., de la Red G., et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004, 63:730-736.
64. Marson P., Bagatella P., Bortolati M., Tison T., De Silvestro G., Fabris F., et al. Plasma exchange for the management of the catastrophic antiphospholipid syndrome: Importance of the type of fluid replacement. J Intern Med 2008, 264:201-203.
65. Ruffatti A., Marson P., Pengo V., Favaro M., Tonello M., Bortolati M., et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 2007, 6:196-202.
66. El-Haieg D.O., Zanati M.F., El-Foual F.M. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. I J Gynaecol Obstet 2007, 99:236-241.
67. Karsh J., Klippel J.H., Plotz P.H., Decker J.L., Wright D.G., Flye M.W. Lymphapheresis in rheumatoid arthritis. A randomized trial. Arthritis Rheum 1981, 24:867-873.
68. Dwosh I.L., Giles A.R., Ford P.M., Pater J.L., Anastassiades T.P. Plasmapheresis therapy in rheumatoid arthritis. A controlled, double-blind, crossover trial. N Engl J Med 1983, 308:1124-1129.
69. Calabrese L.H., Clough J.D., Krakauer R.S., Hoeltge G.A. Plasmapheresis therapy of immunologic disease. Report of nine cases and review of the literature. Cleve Clin Q 1980, 47:53-72.
70. Scott D.G., Bacon P.A., Bothamley J.E., Allen C., Elson C.J., Wallington T.B. Plasma exchange in rheumatoid vasculitis. J Rheumatol 1981, 8:433-439.
71. Bjelle A., Cedergren B., Wahlby L. Plasma exchange in two patients with rheumatoid vasculitis. Scand J Rheumatology 1982, 11:58-62.
72. Gendreau R.M. A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis. Ther Apher 2001, 5:79-83.
73. Dau P.C. Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients. Arch Neurol 1981, 38:544-552.
74. Miller F.W., Leitman S.F., Cronin M.E., Hicks J.E., Leff R.L., Wesley R., et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992, 326:1380-1384.
75. Cherin P., Auperin I., Bussel A., Pourrat J., Herson S. Plasma exchange in polymyositis and dermatomyositis: A multicenter study of 57 cases. Clin Exp Rheumatol 1995, 13:270-271.
76. Braun-Moscovici Y., Furst D.E. Plasmapheresis for rheumatic diseases in the twenty-first century: Take it or leave it?. Curr Opin Rheumatol 2003, 15:197-204.
77. Le Guern V., Guillevin L. Therapeutic apheresis for myositises. Transfus Apher Sci 2007, 36:169-172.
78. Choy E.H., Hoogendijk J.E., Lecky B., Winer J.B., Gordon P. WITHDRAWN: Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2009, CD003643.
79. Cozzi F., Marson P. Plasma-exchange in the treatment of systemic rheumatic diseases: Past and present experience. Reumatismo 2009, 61:161-164.
80. Bandarenko N., Brecher M.E. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher 1998, 13:133-141.
81. Brunskill S.J., Tusold A., Benjamin S., Stanworth S.J., Murphy M.F. A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfusi Med 2007, 17:17-35.
82. Ferrari S., Mudde G.C., Rieger M., Veyradier A., Kremer Hovinga J.A., Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009, 7:1703-1710.